Hugel reports 15 percent revenue growth for first nine months of 2026
South Korean medical aesthetics company Hugel posted net sales of 352.1 billion KRW for the first three quarters of 2026, driven by growth in international and domestic markets.
Hugel Inc. announced its financial results for the first nine months of 2026, reporting consolidated net sales of 352.1 billion KRW, a 15% increase compared to the same period in 2025. Third-quarter net sales reached 97.5 billion KRW, with an operating profit of 18.1 billion KRW and a net profit of 4.7 billion KRW.
The domestic market remains a key driver for the firm, with combined sales of botulinum toxin and dermal fillers rising significantly in South Korea. Internationally, the company recorded growth across Europe, China, and Brazil. In China, the company currently holds the second-largest market share for botulinum toxin at 22%.
In the U.S. market, the company is transitioning from a traditional distributor model to a contract sales organization (CSO) structure. While this shift has impacted short-term results, CEO Carrie Strom stated that the move is intended to unlock strategic benefits and support long-term profitability. The company continues to focus on expanding its portfolio of injectables and cosmetic products globally.